YM Biosciences starts Phase II with Tesmilifene

YM Biosciences (Mississauga, Ontario) began Phase II testing of its Tesmilifine intracellular histamine antagonist in patients with hormone refractory metastatic prostate cancer in the U.S. and Canada...